Cardiovascular Systems recently announced that it has partnered with Chansu Vascular Technologies to develop a new drug-coated balloon technology.
Through the partnership, Cardiovascular Systems and Chansu Vascular Technologies will develop peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems will provide milestone-based financing to Chansu Vascular Technologies for the development of the drug-coated balloons. The deal also includes an acquisition option agreement in which Cardiovascular Systems will have exclusive rights and obligations to acquire the company upon completion of key technical and clinical milestones in the development program.
“This partnership is consistent with our strategic vision to develop an innovative portfolio of new products. We believe these next generation DCBs will complement our current and growing portfolio of products for the treatment of complex coronary and peripheral disease. We are thrilled to be wo…